Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H19FN2O2 |
| Molecular Weight | 302.3434 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NCC1=CC=C(OCC2=CC=CC=C2F)C=C1)C(N)=O
InChI
InChIKey=BHJIBOFHEFDSAU-LBPRGKRZSA-N
InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.prnewswire.com/news-releases/newron-announces-positive-results-with-ralfinamide-from-phase-ii-trial-in-neuropathic-pain-74976442.html
Curator's Comment: Description was created based on several sources, including
http://www.prnewswire.com/news-releases/newron-announces-positive-results-with-ralfinamide-from-phase-ii-trial-in-neuropathic-pain-74976442.html
Priralfinamide, also known as Ralfinamide, FCE-26742A; NW-1029; PNU-0154339E, is a Na-channel blocker for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor. Priralfinamide is in phase Ⅲ clinical trials by Newron for the treatment of chronic neuropathic pain.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.28 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21071997/ |
320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIRALFINAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
41.3 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21071997/ |
320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIRALFINAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21071997/ |
320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIRALFINAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21071997/ |
320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRIRALFINAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
320 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: |
Other AEs: numbness of throat, flu symptoms... Other AEs: numbness of throat (1 pt) Sources: flu symptoms (1 pt) Alanine aminotransferase increase (mild, 1 pt) aspartate aminotransferase (mild, 1 pt) Dizziness (3 patients) Numbness of tongue (2 patients) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| flu symptoms | 1 pt | 320 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: |
| numbness of throat | 1 pt | 320 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: |
| Numbness of tongue | 2 patients | 320 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: |
| Dizziness | 3 patients | 320 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: |
| Alanine aminotransferase increase | mild, 1 pt | 320 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: |
| aspartate aminotransferase | mild, 1 pt | 320 mg single, oral (unknown) Studied dose |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Analysis of human Nav1.8 expressed in SH-SY5Y neuroblastoma cells. | 2005 Dec 28 |
|
| Gateways to clinical trials. | 2005 Jul-Aug |
|
| Gateways to clinical trials. | 2005 Mar |
|
| Effects of ralfinamide, a Na+ channel blocker, on firing properties of nociceptive dorsal root ganglion neurons of adult rats. | 2007 Nov |
|
| Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. | 2008 Oct 15 |
|
| Functional and pharmacological properties of human and rat NaV1.8 channels. | 2009 Apr |
Sample Use Guides
Priralfinamide administered orally at rising doses of 80 - 320 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: Priralfinamide (3–200 uM) inhibition of tetrodotoxinresistant
and tetrodotoxin-sensitive peak current amplitudes
(tonic block) was strictly concentration dependent. Tetrodotoxin-resistant currents, evoked from a pre-conditioning
potential giving maximal current availability (90
mV), were inhibited by ralfinamide with an IC50 value of 72 uM
https://www.ncbi.nlm.nih.gov/pubmed/15763243
In capsaicin-responsive tonic firing nociceptive dorsal root ganglion neurons of adult rats, priralfinamide (25 uM) reduced the number of action potentials (APs) from 10.6+/-1.8 to 2.6+/-0.7 APs/600 ms
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C241
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C75074
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
DTXSID70158406
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107771
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
3LPF0S0GVV
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
DB06649
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
100000089211
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
SUB25211
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
8338
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
Ralfinamide
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
5745207
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY | |||
|
133865-88-0
Created by
admin on Sat Dec 16 16:47:25 GMT 2023 , Edited by admin on Sat Dec 16 16:47:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
